QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.067397v1 310/2/555    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossoni, G. Articles by Berti, F. Search for Related Content PubMed PubMed Citation Articles by Rossoni, G. Articles by Berti, F.

CARDIOVASCULAR

The Nitric Oxide-Releasing Naproxen Derivative Displays Cardioprotection in Perfused Rabbit Heart Submitted to Ischemia-Reperfusion

Departments of Pharmacological Sciences (G.R.) and Pharmacology, Chemotherapy, and Medical Toxicology (G.R., B.M., P.D.S., F.B.), University of Milan, Milan, Italy

In this study, the pharmacological activity of HCT-3012 [(S)-6-methoxy--methyl-2-naphtaleneacetic acid 4-(nitrooxy)butyl ester], a nitric oxide (NO)-releasing derivative of naproxen, was compared with that of naproxen in a model of acute ischemia (40 min) and reperfusion (20 min) of the rabbit heart. HTC-3012 (3–100 µM), in spite of inhibition of 6-keto-prostaglandin F₁ generation by the cardiac tissues, brought about a dose-dependent normalization of coronary perfusion pressure, associated with a reduction of ventricular contracture during ischemia with remarkable improvement of left ventricular developed pressure at reperfusion. These beneficial effects were accompanied by a substantial release of nitrite/nitrate in the heart perfusates, indicating that NO has been released by HCT-3012 and donated to the cardiac tissue. These events were paralleled by a significant reduction of creatine kinase activity in heart perfusates during reperfusion. Naproxen (10–100 µM) aggravated the myocardial damage in ischemic reperfused hearts, severely depressing the postischemic ventricular dysfunction. Perfusion of the heart with N^G-monomethyl-L-arginine (10 µM) caused a marked aggravation of myocardial damage of the reperfused hearts, and this effect was dose dependently prevented by HCT-3012 but not by naproxen. The results of the present experiments clearly indicate that HCT-3012, by donating NO, displays a noticeable anti-ischemic effect in reperfused ischemic rabbit hearts. The safer gastrointestinal profile of HCT-3012 and its ability to control experimental hypertension, suggest that this compound may have therapeutical potential in cardiovascular disease, namely in the prevention of myocardial ischemic events, and may represent a better alternative to conventional nonsteroidal anti-inflammatory drugs.

Address correspondence to: Dr. Giuseppe Rossoni, Department of Pharmacology, Chemotherapy, and Medical Toxicology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy. E-mail: giuseppe.rossoni{at}unimi.it

This article has been cited by other articles:

				J. L. Wallace Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself? Physiol Rev, October 1, 2008; 88(4): 1547 - 1565. [Abstract] [Full Text] [PDF]

				G. Letts and J. Loscalzo Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2863 - 2869. [Abstract] [Full Text] [PDF]

				P. K. Chohan, R. B. Singh, N. S. Dhalla, and T. Netticadan L-Arginine administration recovers sarcoplasmic reticulum function in ischemic reperfused hearts by preventing calpain activation Cardiovasc Res, January 1, 2006; 69(1): 152 - 163. [Abstract] [Full Text] [PDF]